Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma

AIDS

Volumn 21, Issue 10, 2007, Pages 1245-1252

  Bihl, Florian ^a   Mosam, Anisa ^c   Henry, Leah N ^a   Chisholm III, John V ^a   Dollard, Sheila ^d   Gumbi, Pamela ^e   Cassol, Edana ^g,i   Page, Taryn ^c   Mueller, Nicolas ^h   Kiepiela, Photini ^e   Martin, Jeff N ^d   Coovadia, Hoosen M ^f   Scadden, David T ^b,j   Brander, Christian ^a,k  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY OF PRETORIA   (South Africa)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HARVARD STEM CELL INSTITUTE   (United States)

^k Partners AIDS Research Center   (United States)

more..

Author keywords

Chemotherapy; Cytotoxic T lymphocytes; Kaposi's sarcoma; Kaposi's sarcoma associated herpesvirus; Viral immune control; Viral load

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; DOXORUBICIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; SARCOMA, KAPOSI; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 34250017360     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328182df03     Document Type: Article

References (38)

1. World Health Organization. AIDS epidemic update 2005. Available at: http://www.unaids.org/epi/2005/. Accessed: March 2007.
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030-3044.
3. Sissolak G, Mayaud P. AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health 2005; 10:981-992.
4. Ablashi D, Chatlynne L, Cooper H, Thomas D, Yadav M, Norhanom AW, et al. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer 1999; 81:893-897.
5. Chatlynne LG, Ablashi DV. Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol 1999; 9:175-185.
6. Sitas F, Bezwoda WR, Levin V, Ruff P, Kew MC, Hale MJ, et al. Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa. Br J Cancer 1997; 75:1704-1707.
7. Sitas F, Newton R. Kaposi's sarcoma in South Africa. J Natl Cancer Inst Monogr 2000; 28:1-4.
8. Chokunonga E, Levy LM, Bassett MT, Borok MZ, Mauchaza BG, Chirenje MZ, et al. AIDS and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS 1999; 13:2583-2588.
9. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer 2000; 82:1585-1592.
10. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 1999; 319:23-24.
11. Gill PS, Miles SA, Mitsuyasu RT, Montgomery T, McCarthy S, Espina BM, et al. Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 1994; 8:1695-1699.
12. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14:2353-2364.
13. Laubenstein LJ, Krigel RL, Odajnyk CM, Hymes KB, Friedman-Kien A, Wernz JC, et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984; 2:1115-1120.
14. Kaplan L, Abrams D, Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep 1986; 70:1121-1122.
15. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989; 7: 1201-1207.
16. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15:3085-3092.
17. Mosam A, Cassol E, Page T, Bodasing U, Cassol S, Dawood H, et al. Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa. AIDS 2005; 19:441-443.
18. Gill PS, Rarick M, McCutchan JA, Slater L, Parker B, Muchmore E, et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991; 90:427-433.
19. Brander C, Raje N, O'Connor PG, Davies F, Davis J, Chauhan D, et al. Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. Blood 2002; 100:698-700.
20. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 1996; 93:14862-14867.
21. Kiepiela P, Leslie A, Honeyborne J, Ramduth D, Thobakgale C, Chetty S, et al. Coevolutionary influences of HIV and HLA: the dominant role of HLA-B. Nature 2004; 432:769-774.
22. Bihl FK, Loggi E, Chisholm JV III, Hewitt HS, Henry LM, Linde C, et al. Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". J Transl Med 2005; 3:20.
23. Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K, et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006; 176:4094-4101.
24. Stamey FR, Patel MM, Holloway BP, Pellett PE. Quantitative, fluorogenic probe PCR assay for detection of human herpesvirus 8 DNA in clinical specimens. J Clin Microbiol 2001; 39:3537-3540.
25. Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117:858-863.
26. Frahm N, Korber BT, Adams CA, Szinger JJ, Draenert R, Addo MM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78:2187-2200.
27. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18:485-493.
28. Dezube BJ. Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment. Expert Rev Anticancer Ther 2002; 2:193-200.
29. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999; 73:6721-6728.
30. Casazza JP, Betts MR, Picker LJ, Koup RA. Decay kinetics of human immunodeficiency virus-specific CD8R T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 2001; 75:6508-6516.
31. Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, et al. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis 2000; 181:1249-1263.
32. Woodberry T, Suscovich TJ, Henry LM, Martin JN, Dollard S, O'Connor PG, et al. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. J Infect Dis 2005; 192:622-629.
33. Nunez M, Machuca A, Soriano V, Podzamczer D, Gonzalez-Lahoz J. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study Group. AIDS 2000; 14:913-919.
34. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225-232.
35. Curreli F, Cerimele F, Muralidhar S, Rosenthal LJ, Cesarman E, Friedman-Kien AE, et al. Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication. J Virol 2002; 76:5208-5219.
36. Stebbing J, Portsmouth S, Bower M. Insights into the molecular biology and sero-epidemiology of Kaposi's sarcoma. Curr Opin Infect Dis 2003; 16:25-31.
37. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2109-2116.
38. Boivin G, Gaudreau A, Routy JP. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS 2000; 14:1907-1910.